Immunisation Handbook tables

Tables from The Australian Immunisation Handbook, 10th edition

Individual PDFs of all tables, selected figures and the cover information sheets in The Australian Immunisation Handbook, 10th edition, are available from the links below.

The tables have been formatted so that they can be used as standalone resources.

These tables are from the 10th edition of The Australian Immunisation Handbook, used by permission of the Australian Government. The full version of The Australian Immunisation Handbook, 10th edition, including updates, is available from the Australian Government Department of Health Immunise Australia website.

Tables are provided as PDF files. You will require Adobe Acrobat Reader to access these files.

Tables

Table 2.1.1: Pre-vaccination screening checklist [PDF – 24kB] 2015 UPDATE

Table 2.1.2: Responses to relevant conditions or circumstances identified through the pre-vaccination screening checklist [PDF – 217kB] 2016 UPDATE

Table 2.1.3: Live attenuated parenteral and oral vaccines [PDF – 12kB]

Table 2.1.4: False contraindications to vaccination [PDF – 99kB] 2016 UPDATE

Table 2.1.5: Minimum acceptable age for the 1st dose of scheduled vaccines in infants in special circumstances [PDF – 64kB] 2015 UPDATE

Table 2.1.6: Number of vaccine doses that should have been administered by the current age of the child [PDF – 24kB] 2015 UPDATE

Table 2.1.7: Minimum acceptable dose intervals for children <10 years of age [PDF – 57kB] 2015 UPDATE

Table 2.1.8: Catch-up schedule for Haemophilus influenzae type b (Hib) vaccination for children <5 years of age [PDF – 260kB] 2016 UPDATE

Table 2.1.9: Catch-up schedule for 13vPCV (Prevenar 13) for non-Indigenous children, and Indigenous children residing in the Australian Capital Territory, New South Wales, Tasmania and Victoria, who do not have any medical condition(s) associated with an increased risk of invasive pneumococcal disease (IPD), aged <5 years [PDF – 56kB]

Table 2.1.10: Catch-up schedule for 13vPCV (Prevenar 13) for Indigenous children residing in the Northern Territory, Queensland, South Australia or Western Australia ONLY, who do not have any medical condition(s) associated with an increased risk of invasive pneumococcal disease (IPD), aged <5 years [PDF – 60kB]

Table 2.1.11: Catch-up schedule for 13vPCV (Prevenar 13) and 23vPPV (Pneumovax 23) in children with a medical condition(s) associated with an increased risk of invasive pneumococcal disease (IPD), presenting at age <2 years[PDF – 93kB]

Table 2.1.12: Catch-up schedule for persons >=10 years of age (for vaccines recommended on a population level) [PDF – 316kB] 2016 UPDATE

Table 2.2.1: Route of administration for vaccines used in Australia [PDF – 87kB] 2016 UPDATE

Table 2.2.2: Recommended needle size, length and angle for administering vaccines [PDF – 14kB]

Table 2.3.1: Clinical features that may assist differentiation between a vasovagal episode and anaphylaxis [PDF – 164kB] 2015 UPDATE (reference numbers only)

Table 2.3.2: Doses of intramuscular 1:1000 (one in one thousand) adrenaline for anaphylaxis [PDF – 91kB] 2015 UPDATE (reference numbers only)

Table 2.3.3: Contact information for notification of adverse events following immunisation [PDF – 15kB]

Table 3.1.1: Additional vaccines recommended for Indigenous persons, due to their higher risk of disease [PDF – 39kB] 2015 UPDATE

Table 3.2.1: Dose and routes of administration of commonly used vaccines in adult travellers [PDF – 272kB] 2016 UPDATE

Table 3.2.2: Recommended lower age limits of travel vaccines for children [PDF – 52kB] 2015 UPDATE

Table 3.3.1: Recommendations for vaccination in pregnancy [PDF – 202kB] 2016 UPDATE

Table 3.3.2: Recommendations for vaccinations for solid organ transplant (SOT) recipients [PDF – 196kB] 2016 UPDATE (reference numbers only)

Table 3.3.3: Recommendations for revaccination following haematopoietic stem cell transplant (HSCT) in children and adults, irrespective of previous immunisation history [PDF – 192kB] 2016 UPDATE (reference numbers only)

Table 3.3.4: Categories of immunocompromise in HIV-infected persons, based on age-specific CD4+ counts and percentage of total lymphocytes [PDF – 150kB] 2016 UPDATE (reference numbers only)

Table 3.3.5: Recommendations for vaccination in persons with functional or anatomical asplenia [PDF – 54kB] 2015 UPDATE

Table 3.3.6: Recommended intervals between either immunoglobulins or blood products and measles-mumps-rubella (MMR), measles-mumps-rubella-varicella (MMRV) or varicella vaccination [PDF – 108kB] 2016 UPDATE (reference numbers only)

Table 3.3.7: Recommended vaccinations for persons at increased risk of certain occupationally acquired vaccine-preventable diseases [PDF – 39kB] 2015 UPDATE

Table 4.4.1: Recommended doses and schedules for use of inactivated hepatitis A and hepatitis A combination vaccines [PDF – 60kB]

Table 4.5.1: Recommended schedules for use of monovalent hepatitis B and hepatitis B combination vaccines [PDF – 56kB] 2015 UPDATE

Table 4.5.2: Accelerated hepatitis B vaccination schedules (for persons with imminent risk of exposure) [PDF – 51kB]

Table 4.5.3: Post-exposure prophylaxis for non-immune persons exposed to a HBsAg-positive source [PDF – 17kB] 2015 UPDATE

Table 4.7.1: Recommended doses of influenza vaccine [PDF – 164kB] 2016 UPDATE

Table 4.8.1: Recommended doses of JE vaccines [PDF – 44kB] 2015 UPDATE (new table)

Table 4.9.1: Recommendations for measles vaccination with (a) measles-mumps-rubella (MMR) (currently available), and (b) once measles-mumps-rubella-varicella (MMRV) vaccines are available from July 2013 [PDF – 13kB]

Table 4.9.2: Post-exposure prophylaxis required within 72 hours of first exposure for persons exposed to measles [PDF – 48kB] 2015 UPDATE

Table 4.10.1: Recommended number of doses of MenBV by age group [PDF – 43kB] 2015 UPDATE (new table)

List 4.10.1: Conditions associated with an increased risk of invasive meningococcal disease (IMD) in children and adults [PDF – 17kB] 2015 UPDATE (new table)

Table 4.10.2: Recommended use of 4vMenCV by age group for persons with medical condition(s) associated with an increased risk of meningococcal disease [PDF – 35kB] 2015 UPDATE (new table)

Table 4.10.3: Recommended use of 4vMenCV by age group for persons travelling to areas where epidemics of group A, C, W135 or Y meningococcal disease occur or to mass gatherings [PDF – 36kB] 2015 UPDATE (new table)

Table 4.13.1: Recommendations for pneumococcal vaccination for children aged <5 years [PDF – 18kB]

List 4.13.1: Conditions associated with an increased risk of invasive pneumococcal disease (IPD) in children and adults, by severity of risk [PDF – 65kB]

Table 4.13.2: Recommendations for pneumococcal vaccination for children aged 2–5 years with a medical condition(s) associated with an increased risk of invasive pneumococcal disease (IPD) [PDF – 50kB]

Table 4.13.3: Recommendations for pneumococcal vaccination using 23vPPV for adults who do not have a condition(s) associated with an increased risk of invasive pneumococcal disease (IPD) [PDF – 56kB]

Table 4.15.1: Interpretation and action for serological and skin test results (with modifications from A guide to Q fever and Q fever vaccination (CSL Biotherapies, 2009)) [PDF – 14kB]

Table 4.16.1: Lyssavirus exposure categories [PDF – 8kB] 2015 UPDATE (reference numbers only)

Table 4.16.2: Post-exposure prophylaxis commenced overseas and recommended completion in Australia [PDF – 18kB] 2015 UPDATE

Table 4.17.1: Upper age limits for dosing of oral rotavirus vaccines [PDF – 15kB]

Table 4.19.1: Guide to tetanus prophylaxis in wound management [PDF – 58kB]

Table 4.22.1: Recommendations for varicella vaccination with (a) monovalent varicella vaccine (VV) (currently available), and (b) once measles-mumps-rubella-varicella (MMRV) vaccines are available from July 2013 [PDF – 13kB]

Table 4.22.2: Zoster immunoglobulin-VF (ZIG) dose based on weight [PDF – 21kB]

Table A2.1: Electronic databases searched for the 10th edition [PDF – 13kB]

Table A3.1: Components of vaccines used in the National Immunisation Program [PDF – 30kB]

Table A7.1: Key dates when vaccines first came into widespread use in Australia

[PDF – 16kB]


Figures

Figure 2.1.1: Catch-up worksheet for children <10 years of age for NIP vaccines [PDF – 19kB]

Figure 4.16.1: Post-exposure prophylaxis algorithm for potential exposure to lyssaviruses from a terrestrial animal in a rabies-enzootic area [PDF – 63kB] 2015 UPDATE

Figure 4.16.2: Post-exposure prophylaxis algorithm for potential exposure to lyssaviruses from bats in Australia or overseas [PDF – 90kB]

Figure 4.16.3: Booster algorithm for persons at ongoing risk of exposure to either rabies or other lyssaviruses, including Australian bat lyssavirus (ABLV) [PDF – 41kB]


Cover information sheets

Information sheet – Adverse events following immunisation, Side effects following immunisation for vaccines used in the National Immunisation Program (NIP) schedule  (Inside front cover) [PDF – 98kB]

Information sheet – Comparison of the effects of diseases and the side effects of NIP vaccines (Inside back cover) [PDF – 26kB]

Recognition and treatment of anaphylaxis (Back cover) [PDF – 22kB]

 

Last updated August 2016